| Identification | Back Directory | [Name]
Tazifylline | [CAS]
79712-55-3 | [Synonyms]
Tazifilina
Tazifylline
Tazifyllinum
Tazifylline [inn]
Tazifyllinum [latin]
Tazifilina [spanish]
79712-53-1 (Dihydrochloride)
3,7-Dihydro-7-[2-hydroxy-3-[4-[3-(phenylthio)propyl]piperazin-1-yl]propyl]-1,3-dimethyl-1H-purine-2,6-dione
1H-Purine-2,6-dione, 3,7-dihydro-7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)-1-piperazinyl)propyl)-1,3-dimethyl- | [Molecular Formula]
C23H32N6O3S | [MDL Number]
MFCD00865706 | [MOL File]
79712-55-3.mol | [Molecular Weight]
472.6 |
| Chemical Properties | Back Directory | [Boiling point ]
705.1±70.0 °C(Predicted) | [density ]
1.34±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
14.27±0.20(Predicted) |
| Hazard Information | Back Directory | [Uses]
Antihistaminic. | [in vivo]
In rats, guinea pigs and dogs the antihistaminic effect of Tazifylline is rapid in onset and long-lived. In anesthetized guinea pigs, Tazifylline markedly inhibits histamine-induced bronchoconstriction and protects conscious animals from the lethal effect of large doses of the amine. In conscious rats, Tazifylline is more potent in reducing the inflammatory effects of intradermal histamine than that evoked by anaphylactic reaction. In conscious dogs, orally administered Tazifylline inhibits histamine-induced skin inflammation for long periods of time and in anesthetized animals attenuated that portion of the histamine-evoked hypotension attributable to stimulation of H1-receptors. Large oral doses of Tazifylline does not reduce spontaneous locomotor activity in mice, nor do they produce overt symptoms of behavioral depression in conscious rats[1]. | [storage]
Store at -20°C |
|
| Company Name: |
cjbscvictory
|
| Telephone: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
|